

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/667,966 Confirmation No.: 7892
Applicant : Dong XIE *et al*
Filed : September 23, 2003
Title : PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV
INFECTION
TC/Art Unit : 1648
Examiner: : Jeffrey PARKIN, Ph.D.
Docket No. : 63024.000002
Customer No. : **21967**

MAIL STOP AMENDMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

LETTER REGARDING SUBSTANCE OF TELEPHONIC INTERVIEW

Sir,


In accordance with 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04, Applicants herein provide a summary of the telephonic interview of January 31, 2008 between Larry Posorske, Ph.D., Robert Lampe, III, and Examiner Jeffrey Parkin, Ph.D. Applicants appreciate the courtesy of the telephonic interview extended by the Examiner. Applicants' representatives contacted the Examiner concerning the status of the amendment-after-final submitted October 30, 2007. During the telephonic interview, the USPTO alleged that additional prior art was identified that renders SEQ ID NOs: 12 and 13 unpatentable. During the telephonic interview, the USPTO alleged that the prior art anticipates and/or renders these sequences obvious. It was stated that the finality of the last office action has been withdrawn, the amendment-after-final submitted October 30, 2007, will be entered, and an office action setting forth new grounds of rejection will be forthcoming.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: March 5, 2008

By:


Laurence H. Posorske, Ph.D.
Registration No. 34,698

HUNTON & WILLIAMS LLP
Intellectual Property Department
1900 K Street, N.W., Suite 1200
Washington, DC 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

Robert C. Lampe III
Registration No. 51,914

LHP/CJN:cdh